产品
编 号：F535925
分子式：C17H28N2O5
分子量：340.41
分子式：C17H28N2O5
分子量：340.41
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 95153-31-4
产品详情
生物活性：
Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research.
体内研究：
Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment improves cardiac function in mice with acute myocardial infarction and reduces the number of apoptotic myocardial cells.Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment reduces the expression levels of myocardial Bax and Bcl-2 in infarction zones of mice with acute myocardial infarction.Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment lowers the expression of myocardial TLR4/NF-κB in infarction zones in mice with acute myocardial infarction.Animal Model:C57BL/6J mice underwent coronary ligation
Dosage:1.5 mg/kg
Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days
Result:Exhibited markedly lowered the number of apoptotic myocardial cells in comparison with the acute myocardial infarction group (p<0.05).
Animal Model:C57BL/6J mice underwent coronary ligation
Dosage:1.5 mg/kg
Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days
Result:Reduced the gene and protein expression levels of Bax (a myocardial apoptosis gene) in infarction zones in mice with acute myocardial infarction.
Animal Model:C57BL/6J mice underwent coronary ligation
Dosage:1.5 mg/kg
Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days
Result:Declined the number of stained NF-κB p50 protein in the nucleus in infarction zones (p<0.05), compared to the acute myocardial infarction group.
体外研究：
Perindoprilat (1 μM, 10 days) treatment suppresses the angiotensin II production in HNSCC cells.Perindoprilat (40 μM, 3 days) treatment attenuates mesangial cell fibronectin level.
Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research.
体内研究：
Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment improves cardiac function in mice with acute myocardial infarction and reduces the number of apoptotic myocardial cells.Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment reduces the expression levels of myocardial Bax and Bcl-2 in infarction zones of mice with acute myocardial infarction.Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment lowers the expression of myocardial TLR4/NF-κB in infarction zones in mice with acute myocardial infarction.Animal Model:C57BL/6J mice underwent coronary ligation
Dosage:1.5 mg/kg
Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days
Result:Exhibited markedly lowered the number of apoptotic myocardial cells in comparison with the acute myocardial infarction group (p<0.05).
Animal Model:C57BL/6J mice underwent coronary ligation
Dosage:1.5 mg/kg
Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days
Result:Reduced the gene and protein expression levels of Bax (a myocardial apoptosis gene) in infarction zones in mice with acute myocardial infarction.
Animal Model:C57BL/6J mice underwent coronary ligation
Dosage:1.5 mg/kg
Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days
Result:Declined the number of stained NF-κB p50 protein in the nucleus in infarction zones (p<0.05), compared to the acute myocardial infarction group.
体外研究：
Perindoprilat (1 μM, 10 days) treatment suppresses the angiotensin II production in HNSCC cells.Perindoprilat (40 μM, 3 days) treatment attenuates mesangial cell fibronectin level.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备